PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2026-01-08

Date Title Company
08-Jan-2026 Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity Businesswire
08-Jan-2026 Cellarity Provides Strategic Priorities and Outlook for 2026 Businesswire
08-Jan-2026 CellVoyant launches new online predictive cell analytics platform to fast-track drug development CellVoyant
08-Jan-2026 Enodia Therapeutics Secures €20.7M to Advance a Small-Molecule Platform for Targeted Protein Degradation Enabled by Proteomics and Machine Learning Enodia Therapeutics
08-Jan-2026 Candid Therapeutics Plans to Initiate Multiple Phase 2 Studies Following Promising Clinical Data of T-cell Engagers in Autoimmune Diseases Businesswire
08-Jan-2026 Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit Businesswire
08-Jan-2026 Virometix AG Announces Positive Data from Phase 1 Trial of V-212, a Fully Synthetic, Serotype-Independent Vaccine Development Candidate for the Prevention of Pneumococcal Disease Businesswire
08-Jan-2026 Tubulis Appoints Charles Fuchs, MD as Chief Medical Officer to Lead Clinical Strategy and Pipeline Development Businesswire
08-Jan-2026 Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook Businesswire
08-Jan-2026 Osel Enters Agreement with SWOG Cancer Research Network for First-Ever Pivotal Trial of a Microbiome-Based Therapy in Oncology Businesswire
08-Jan-2026 ScribeRyte AI Receives Top A/A+* Grades in KLAS First Look Survey for Reducing Clinical Documentation Burden with Accurate, Efficient, AI-Powered Scribe Solutions ScribeRyte AI
08-Jan-2026 AstronauTx appoints experienced biotech executive Adam Rosenberg as Chair of the Board AstronauTx
08-Jan-2026 Lonza’s Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next‑Generation Bispecific ADCs Lonza’s Synaffix
08-Jan-2026 Nucleome Therapeutics nominates first preclinical development candidate Nucleome Therapeutics
08-Jan-2026 STORM Therapeutics and AlidaBio Announce Strategic Collaboration to Accelerate Development of Cancer Therapies Targeting RNA Modifications STORM Therapeutics
08-Jan-2026 Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines NanoSyrinx
08-Jan-2026 NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS/MND and Parkinson’s NRG Therapeutics
08-Jan-2026 EnteroBiotix announces positive Phase 2 TrIuMPH results supporting EBX-102-02 as a potential first-in-class, oral, full-spectrum microbiome therapy for irritable bowel syndrome EnteroBiotix
08-Jan-2026 Advanced Therapies Week 2026: Phacilitate Unites CGT Community for New Era Defined by Innovation and Collaboration Advanced Therapies
08-Jan-2026 Alceus Bio awarded Pioneer Group and AbbVie’s Golden Ticket Alceus Bio , Abbvie, Pioneer Group